A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05569759 |
|
Recruitment Status :
Recruiting
First Posted : October 6, 2022
Last Update Posted : December 5, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Autoimmune Hepatitis | Drug: zetomipzomib Drug: placebo Drug: zetomipzomib in open-label extension | Phase 2 |
This is a Phase 2a, multi-center, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate safety, tolerability, and efficacy of zetomipzomib in patients with autoimmune hepatitis (AIH) who have not benefited from standard-of-care treatment, had an incomplete response to ≥3 months of standard-of-care treatment, or had a disease flare after standard of care.
Zetomipzomib or placebo will be administered weekly for a 24-week treatment period in addition to standard-of-care (glucocorticoids), followed by a 4-week off-treatment safety follow-up period. Zetomipzomib and placebo will be administered subcutaneously (SC) once weekly.
At the end of the 24-week treatment period, eligible patients from both the zetomipzomib- and placebo-treated arms who complete the double-blind treatment period can enroll in the open-label extension period to receive an additional 24 weeks of treatment with zetomipzomib.
Primary completion date represents the anticipated completion date of the double-blind portion of the study. Study completion date represents the anticipated completion date of the open-label extension portion of the study.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 24 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With Open-label Extension to Evaluate the Safety and Efficacy of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis |
| Actual Study Start Date : | May 23, 2023 |
| Estimated Primary Completion Date : | September 2024 |
| Estimated Study Completion Date : | March 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: zetomibzomib + standard-of-care (glucocorticoids)
Initial 30 mg dose of zetomipzomib, followed by weekly 60 mg doses of zetomipzomib, for the remaining 23 weeks of the treatment period.
|
Drug: zetomipzomib
Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
Other Name: KZR-616 |
|
Placebo Comparator: placebo + standard-of-care (glucocorticoids)
Initial 30 mg dose of placebo (sterile water for injection), followed by weekly 60 mg doses of placebo, for the remaining 23 weeks of the treatment period.
|
Drug: placebo
Subcutaneous injection of placebo
Other Name: sterile water for injection |
|
Experimental: zetomipzomib + standard-of care (glucocorticoids) open-label extension period
Initial 30 mg dose of zetomipzomib at the open-label extension (OLE) Week 1 visit, followed by weekly doses of 60 mg of zetomipzomib, for a total of 24 additional weeks of treatment.
|
Drug: zetomipzomib in open-label extension
Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
Other Name: KZR-616 |
- To evaluate the efficacy of zetomipzomib [ Time Frame: Week 24 ]Proportion of patients who achieve complete biochemical remission (CR) with successful glucocorticoid taper by Week 24.
- To evaluate the safety and tolerability of zetomipzomib [ Time Frame: Baseline through 28 weeks. ]Proportion of patients who experience AEs (adverse events) and SAEs (serious adverse events), including incidence and severity of AEs and SAEs, incidence of AEs leading to drug discontinuation, and changes in laboratory parameters and vital signs.
- To evaluate the efficacy of zetomipzomib during the open-label extension period [ Time Frame: Start of open-label extension (OLE) period through End of Study (EOS) at OLE Week 29 ]Proportion of patients experiencing a disease flare among the patients who achieved a complete biochemical remission (CR) during the double-blind treatment period.
- Alanine aminotransferase (ALT) [ Time Frame: Week 24 ]Mean changes from baseline in alanine aminotransferase (ALT)
- Partial Remission [ Time Frame: Week 24 ]Proportion of patients who achieve a partial remission (PR)
- Time to complete remission [ Time Frame: Baseline through Week 24 ]Time to complete remission (CR)
- Time to partial remission [ Time Frame: Baseline through Week 24 ]Time to partial remission (PR)
- Plasma concentrations of zetomipzomib and its metabolites [ Time Frame: Baseline through Week 16 ]Maximum plasma concentration [Cmax]
- Plasma concentrations of zetomipzomib and its metabolites [ Time Frame: Baseline through Week 16 ]Time of maximum plasma concentration [Tmax]
- Plasma concentrations of zetomipzomib and its metabolites [ Time Frame: Baseline through Week 16 ]Area under the concentration-time curve [AUC]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Key Inclusion Criteria for the Double-blind Treatment Period:
-
Must be aged ≥18 years.
-
Must have a clinical diagnosis of AIH and signs of active disease despite standard-of-care therapy for ≥3 months or disease flare after experiencing complete remission induced by standard-of-care treatment, including:
- Screening ALT values that are 1.25 to 10 times the upper limit of the normal range (ULN)
- Liver biopsy results with Ishak score (modified HAI) ≥5/18 indicating active AIH, from a biopsy performed at Screening, or within 6 months prior to Screening
- Mild or no hepatic impairment (Child Pugh category A)
- Must be willing to use and taper glucocorticoid therapy.
- Must be willing to use effective contraception.
-
Key Exclusion Criteria for the Double-blind Treatment Period:
- Have a concomitant diagnosis of primary biliary sclerosis, primary sclerosing cholangitis, IgG 4 related cholangitis, drug related AIH (at Screening) or a history of drug-related AIH.
- Have clinical evidence of significant unstable or uncontrolled diseases other than the disease under study.
- Are receiving oral or injectable immunomodulating treatment for any other autoimmune disease prior to enrollment in the study. Patients who have been using such treatments must follow the specified washout periods.
- Have an active infection (eg, acute hepatitis E, cytomegalovirus, or Epstein-Barr virus) requiring systemic therapy with antibiotic, antiviral, or antifungal treatment, or has had any febrile illness within 7 days prior to Day -1.
- Have a history of thyroiditis, celiac disease, or other autoimmune disorder known to be associated with transaminitis.
- Have liver cirrhosis with significant impairment of liver function (Child Pugh category B or C) or have decompensated cirrhosis.
- Patients with histology confirmed coincident non-alcoholic steatohepatitis.
Key Inclusion Criteria for the Open-label Extension Period:
-
Same as Double-blind Treatment Period inclusion criteria, except the following modifications:
- ALT value can be normal or, if elevated, in the range of 1.25 to 10 times the upper limit of normal
- Must have completed the Double-blind Period study visits through Week 24, including all Week 24 Visit assessments.
- Must be willing to maintain glucocorticoid therapy at 5 mg/day or continue to taper glucocorticoid therapy.
Key Exclusion Criteria for the Open-label Extension Period:
•. Same as Double-blind Treatment Period except no need to re-test for HIV, HBV, HCV, and TB.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05569759
| Contact: Kezar Life Sciences, Inc. | (650) 822-5600 | PORTOLA@kezarbio.com |
Show 24 study locations
| Principal Investigator: | Craig Lammert, MD | Indiana University | |
| Principal Investigator: | Ethan Weinberg, MD | University of Pennsylvania |
| Responsible Party: | Kezar Life Sciences, Inc. |
| ClinicalTrials.gov Identifier: | NCT05569759 |
| Other Study ID Numbers: |
KZR-616-208 |
| First Posted: | October 6, 2022 Key Record Dates |
| Last Update Posted: | December 5, 2023 |
| Last Verified: | December 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
immunoproteasome inhibition selective proteasome inhibition disease flare Liver enzymes |
ALT (alanine aminotransferase) AST (aspartate aminotransferase) glucocorticoids steroids |
|
Hepatitis A Hepatitis Hepatitis, Autoimmune Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases |
Infections Enterovirus Infections Picornaviridae Infections RNA Virus Infections Hepatitis, Chronic Autoimmune Diseases Immune System Diseases |